AndreaBozzo/ceres-open-data-index huggingface dataset:
Ecstasy-Related Emergency Department Visits by Young People Increased between 2005 and 2011; Alcohol Involvement Remains a Concern

This spotlight report describes the risks of combining the drug Ecstasy (also known as MDMA or methylenedioxymethamphetamine) with alcohol. For emergency department patients aged 20 and younger, it provides the number of emergency department visits that involved Ecstasy, and the percentage of Ecstasy-related visits that involved alcohol for the years 2005 through 2011.
Compound 530691: 2,3,4-Trifluorobenzoic acid, but-3-yn-2-yl ester

Chemical compound data from PubChem database. IUPAC Name: but-3-yn-2-yl 2,3,4-trifluorobenzoate. Molecular Formula: C11H7F3O2. Molecular Weight: 228.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2010 CMHS Uniform Reporting System (URS) Output Tables for Maryland

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs

Background
          The search for an optimal experimental model in pharmacology is recently focused on (mini)pigs as they seem not only to be an alternative source of cells and tissues for xenotherapy but also an alternative species for studies on drug metabolism in man due to similarities between (mini) pig and human drug metabolizing systems. The purpose of this work is to characterize minipig liver microsomal cytochromes P450 (CYPs) by comparing their N-terminal sequences with corresponding human orthologs.
        
        
          Results
          The microsomal CYPs exhibit similar activities to their human orthologous enzymes (CYP3A4, nifedipine oxidation; 2A6, coumarin 7-hydroxylation; 2D6, bufuralol 1'-hydroxylation; 2E1, p-nitrophenol hydroxylation; and 2C9, tolbutamide hydroxylation). Specific minipig CYP (2A, 2C and 3A) enzymes were partially purified and proteins identified by immunostaining (using antibodies against the respective human CYPs) were used for N-terminal amino acid sequencing. From comparisons, it can be concluded that the sequence of the first 20 amino acids at the N-terminus of minipig CYP2A is highly similar to human CYP2A6 (70% identity). The N-terminal sequence of CYP2C shared about 50% similarity with human 2C9. The results on the minipig liver microsomal CYP3A yielded identical data with those obtained for amino acid sequences of the pig CYP3A29 showing 60% identity with human CYP3A4.
        
        
          Conclusions
          Thus, our results further support the view that minipigs may serve as model animals in pharmacological/toxicological studies with substrates of human CYP enzymes, namely, of the CYP3A and CYP2A forms.
2014 CMHS Uniform Reporting System (URS) Table for New York

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for New York. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Long-Term Services and Supports Measures and Dashboard Data

The Department of Health Care Services (DHCS) Long-Term Services and Supports (LTSS) Data Dashboard is an initiative of the [Home and Community Based Services Spending Plan](https://www.dhcs.ca.gov/provgovpart/Pages/HCBS.aspx). The initiative's primary goal is to create a public-facing LTSS data dashboard to track demographic, utilization, quality, and cost data related to LTSS services. This dashboard will link statewide long-term care and home and community-based services (HCBS) data with the goal of increased transparency to make it possible for regulators, policymakers, and the public to be informed while the state continues to expand, enhance, and improve the quality of LTSS in all home, community, and congregate settings.

The first iteration of the LTSS Dashboard was released in December 2022 as an Open Data Portal file with 40 measures pertaining to LTSS beneficiaries, which includes ten different demographics, plan-related dimensions, and dual stratification. The December 2023 Data Release includes 16 new measures on the Medi-Cal LTSS Dashboard and Open Data Portal (Select “View Underlying Data”); and additional measures and dimensions, including dual stratification, will be added to the Open Data Portal in 2024.

Note: The LTSS Dashboard measures are based on certified eligible beneficiaries who were enrolled in Medi-Cal for one or more months during the reporting interval. Most of the DHCS LTSS dashboard measures report the annual number of certified eligible Medi-Cal beneficiaries who have used LTSS services within a year. Other departments may report on these programs differently. For example, the Department of Social Services (CDSS) reports monthly [IHSS recipient/consumer](https://www.cdss.ca.gov/inforesources/ihss/program-data) counts. The California Department of Aging (CDA) reports monthly [CBAS Medi-Cal participants](https://aging.ca.gov/Providers_and_Partners/Community-Based_Adult_Services/Center_Overview/). DHCS’ annual utilization / enrollment counts of IHSS and CBAS beneficiaries are larger than CDSS/CDA's monthly counts because of data source differences and new enrollment or program attrition over time. Monthly snap-shot measures (average monthly utilization) for IHSS and CBAS have been added to the LTSS Dashboard to align with CDSS and CDA monthly reporting.

Refer to the [LTSS-Dashboard (ca.gov)](https://www.dhcs.ca.gov/services/Pages/LTSS-Dashboard.aspx) program page for: 
1) a Fact Sheet with highlights from the initial data release including changes over time in use of Home and Community-Based Services as well as select demographic information; 
2) the Measure Specifications document – that describes business rules and inclusion/exclusion criteria related to age groups, plan types, aid code, geographic, or other important program/waiver-specific eligibility criteria; and 
3) User guide –  that shows how to navigate the Open Data Portal data file with specific examples.
Patent AT-E401135-T1: [Translated] DISPENSING DEVICE

A manually-actuated device for the deliver of a volume of liquid which includes an outlet through which liquid is in use delivered and a cover member which is movably disposed relative to the housing between a first position in which the cover member at least partly covers the outlet and a second position in which the cover member acts as a lever which in use is acted upon by a user to actuate the delivery device.
Patent AT-E401775-T1: [Translated] HAND-HELD TILLING EQUIPMENT, IN PARTICULAR LAWN MOWERS

Hand guided soil cultivation appliance has a mobile housing with a guiding handle (5), which is running diagonally upward for the operator. A positive locking, with elastic pre-stress, works in such a manner that the guiding handle, for positive locking with its cooperative housing part, jump out of the positive locking when the locking lever (8) is adjusted from the locking position to the release position.
Control of dinucleoside polyphosphates by the

Background
          The FHIT gene is lost early in the development of many tumors. Fhit possesses intrinsic ApppA hydrolase activity though ApppA cleavage is not required for tumor suppression. Because a mutant form of Fhit that is functional in tumor suppression and defective in catalysis binds ApppA well, it was hypothesized that Fhit-substrate complexes are the active, signaling form of Fhit. Which substrates are most important for Fhit signaling remain unknown.
        
        
          Results
          Here we demonstrate that dinucleoside polyphosphate levels increase 500-fold to hundreds of micromolar in strains devoid of the Saccharomyces cerevisiae homolog of Fhit, Hnt2. Accumulation of dinucleoside polyphosphates is reversed by re-expression of Hnt2 and is active site-dependent. Dinucleoside polyphosphate levels depend on an intact adenine biosynthetic pathway and time in liquid culture, and are induced by heat shock to greater than 0.1 millimolar even in Hnt2+ cells.
        
        
          Conclusions
          The data indicate that Hnt2 hydrolyzes both ApppN and AppppN in vivo and that, in heat-shocked, adenine prototrophic yeast strains, dinucleoside polyphosphates accumulate to levels in which they may saturate Hnt2.
2011 CMHS Uniform Reporting System (URS) Output Tables for New Mexico

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 529941: 1-[2-Methyl-(3-furyldithio)]butan-2-one

Chemical compound data from PubChem database. IUPAC Name: 1-[(2-methylfuran-3-yl)disulfanyl]butan-2-one. Molecular Formula: C9H12O2S2. Molecular Weight: 216.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399535-T1: [Translated] METHOD FOR PRODUCING MICROPARTICLES WITH A SELECTED POLYMER MOLECULAR WEIGHT

The present invention provides a method for preparing microparticles having a selected polymer molecular weight. The hold time and temperature of a solution containing a nucleophilic compound and a polymer having a starting molecular weight are controlled in order to control the molecular weight of the polymer in the finished microparticle product. In this manner, a selected polymer molecular weight in the finished microparticle product can be achieved from a variety of starting material molecular weights.
Trends in Nonmedical Use of Prescription Pain Relievers: 2002 to 2007

This report uses NSDUH data from 2002 to 2007 on Prescription Pain Relievers.  In 2007, 2.1 percent of persons aged 12 or older (an estimated 5.2 million persons) reported using prescription pain relievers nonmedically in the past month; this rate does not differ significantly from that in 2002.
The Child Welfare Information Technology System Project Lifecycle, Part 2

Through the webinar series, “Back to Basics”, the Division of State Systems within the Children’s Bureau, is offering a venue for information sharing and discussion. The third webinar of the series, “The Child Welfare Information Technology System Project Lifecycle, Part 2”, reviews the project stages including implementation, maintenance and operation, and Federal requirements. Two experienced child welfare Information System managers share their perspectives on this subject.

Metadata-only record linking to the original dataset. Open original dataset below.
Long-term reductions in tinnitus severity

Background
          This study was undertaken to assess long-term changes in tinnitus severity exhibited by patients who completed a comprehensive tinnitus management program; to identify factors that contributed to changes in tinnitus severity within this population; to contribute to the development and refinement of effective assessment and management procedures for tinnitus.
        
        
          Methods
          Detailed questionnaires were mailed to 300 consecutive patients prior to their initial appointment at the Oregon Health & Science University Tinnitus Clinic. All patients were then evaluated and treated within a comprehensive tinnitus management program. Follow-up questionnaires were mailed to the same 300 patients 6 to 36 months after their initial tinnitus clinic appointment.
        
        
          Results
          One hundred ninety patients (133 males, 57 females; mean age 57 years) returned follow-up questionnaires 6 to 36 months (mean = 22 months) after their initial tinnitus clinic appointment. This group of patients exhibited significant long-term reductions in self-rated tinnitus loudness, Tinnitus Severity Index scores, tinnitus-related anxiety and prevalence of current depression. Patients who improved their sleep patterns or Beck Depression Inventory scores exhibited greater reductions of tinnitus severity scores than patients who continued to experience insomnia and depression at follow-up.
        
        
          Conclusions
          Individualized tinnitus management programs that were designed for each patient contributed to overall reductions in tinnitus severity exhibited on follow-up questionnaires. Identification and treatment of patients experiencing anxiety, insomnia or depression are vital components of an effective tinnitus management program. Utilization of acoustic therapy also contributed to improvements exhibited by these patients.
Compound 526190: 2-Methyl-2-tetrahydrothiophenethiol

Chemical compound data from PubChem database. IUPAC Name: 2-methylthiolane-2-thiol. Molecular Formula: C5H10S2. Molecular Weight: 134.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399989-T1: [Translated] METHOD AND DEVICE FOR MEASURING CHEMICAL AND/OR BIOLOGICAL SAMPLES

A device for the measurement of chemical and/or biological samples, in particular by means of luminescence spectroscopy, comprises an irradiation unit (12), a sample receiver (10), at least one optical unit (30) and a detector unit (40). Electromagnetic radiation of various wavelength ranges and/or polarisations are led to the sample (10) from the irradiation unit (12). The colour marker in the sample (10), which contains at least one colour marker, is stimulated into producing luminescence and gives off light. The emitted light is led by means of an optical unit in the direction of an optical unit. The light emitted by the colour markers is detected by detectors (42,44,46, 48) in the detector unit. According to the invention, the measurement results may be improved on the irradiation unit (12) generating a pulsed irradiation. The irradiation unit is thus preferably controlled by a control unit (18) in such a way that the irradiation pulses impinge on the sample (10) in a temporal sequence.
Compound 528713: Methyl 2-propenyl pentasulfide

Chemical compound data from PubChem database. IUPAC Name: 3-(methylpentasulfanyl)prop-1-ene. Molecular Formula: C4H8S5. Molecular Weight: 216.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
University of Illinois at Chicago Health Policy Center - Funding

1991-2016. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System.  Funding Data, Appropriations (1991-2016) and Expenditures (2008-2016).  Appropriations data show public funds allocated to/by a particular state for tobacco prevention and control.  They are not necessarily expended.  Appropriations are from four major funding sources, Federal, state, Robert Wood Johnson Foundation (RWJF), and the American Legacy Foundation (Legacy).  Expenditures are amounts spent by state tobacco control programs on tobacco prevention and control.  Expenditure data are available by CDC Best Practices Program Components (State and Community Interventions, Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Administration and Management). Expenditures from 2008 to 2014 are compared against 2007 CDC Best Practices Recommendations; expenditures from 2015 and forward are compared against 2014 CDC Best Practices Recommendations.
Compound 528058: N,O-Bis(dimethyl-t-butylsilyl)-l-glycine

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[[tert-butyl(dimethyl)silyl]amino]acetate. Molecular Formula: C14H33NO2Si2. Molecular Weight: 303.59. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
State Child Abuse and Neglect (SCAN) Policies Database 2019-2023

The SCAN Policies Database includes state definitions and policies from the 50 states, the District of Columbia, and the Commonwealth of Puerto Rico. The SCAN Policies Database 2019 represents data, collected, reviewed, and verified between May 2019 and July 2020, and the data reflect the state definitions and policies for the calendar year 2019. The SCAN Policies Database 2021 represents data collected, reviewed, and verified between July 2021 and January 2022, and the data reflect the state definitions and policies for the calendar year 2021. The SCAN Policies Database 2023 represents data, collected, reviewed, and verified between May 2023 and July 2024, and the data reflect the state definitions and policies for the calendar year 2023.

Investigators: Elizabeth C. Weigensberg, PhD - 
Mathematica
Nuzhat Islam, MS - 
Mathematica
Jean Knab, PhD - 
Mathematica
Mary A. Grider, MBA - 
Mathematica
Jeremy Page, MA - 
Mathematica
Sarah Bardin, BA - 
MathematicaAddison Larson, MS - MathematicaMilena Raketic, , M.Ed  -Mathematica
COVID-19 Dashboard

The dashboard is updated each Friday.

__Laboratory surveillance data__: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for COVID-19 in California. Test positivity for a given week is calculated by dividing the number of positive COVID-19 results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday.

__Hospitalization data__: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset (https://dof.ca.gov/forecasting/demographics/projections/) provided by the State of California Department of Finance. Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html). Weekly hospitalization data are defined as Sunday through Saturday.

__Death certificate data__: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday.
Innovation Center Model Awardees

The Innovation Center Model Awardees dataset provides information about institutions that have participated in the model process, and have been awarded funding based on their efforts to design, implement, or test innovative healthcare delivery initiatives. The data includes the name of the institution, related keywords, project name, geographic reach, funding amount, real or projected 3-year savings, a summary of the institutions activities in the model, categories related to the type of healthcare initiative, stage of participation, and the URL for the model or initiative page on the CMMI website.
Patent AT-E399750-T1: [Translated] HYDROFORMYLATION PROCESS FOR CONVERTING AN ETHYLENEICALLY UNSATURATED COMPOUND INTO AN ALCOHOL

The invention pertains to a hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol comprising a first step of reacting at an elevated temperature in a reactor the ethylenically unsaturated compound, carbon monoxide, hydrogen, and a phosphine-containing cobalt hydroformylation catalyst, which are dissolved in a solvent, followed by a second step of separating a mixture comprising the alcohol and heavy ends from a solution comprising the catalyst and the solvent, followed by a third step of recycling the solution to the reactor.
Patent AT-E401267-T1: [Translated] VACUUM CONVEYOR WITH ROTATING AIR FEED

The conveyor has a conveyor belt (2) for transport of plate-form tools, where the conveyor is rotatably driven by two guide rollers (4, 5). A compressed air is introduced into suction blocks (6, 6a). The rollers are designed as air distributors, over which the air is introduced to the lower side of the belt over channels. Coupling holes (9) stay in connection with the belt, over which the air is introduced in the blocks.
Mesalamine

Mesalamine is a prescription medication in delayed-release capsule form (400 mg) used to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease. It belongs to the aminosalicylate class and works by reducing inflammation in the colon. Manufactured by Teva Pharmaceuticals USA, Inc., it's available as a generic under ANDA 207873. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400912-T1: [Translated] IGNITION DEVICE WITH PRE-IGNITION CHAMBER MADE OF A MATERIAL WITH HIGH THERMAL CONDUCTIVITY, FOR COMBUSTION ENGINE AND IGNITOR WITH PRE-IGNITION CHAMBER

An ignition system for an internal combustion engine comprises: (a) a main combustion chamber (1) destined to contain a main fuel mixture, and equipped with a compression system; (b) an ignitor (11) incorporating a precombustion chamber (2) destined to receive some reactives and an ignition system (13, 14) for the reactives contained in the precombustion chamber; (c) the precombustion chamber is defined by a body (12) having a head (12a) incorporating at least one passage (15); (d) the head separates the precombustion chamber from the main chamber, which are connected by passages in the head; (e) the body of the precombustion chamber is made in a material with a thermal conductivity at 20 degrees Celsius of at least 10 W/K/m. An Independent claim is also included for an ignitor for an internal combustion engine incorporating a precombustion chamber.
Role of endothelin-1 in lung disease

Endothelin-1 (ET-1) is a 21 amino acid peptide with diverse biological activity that has been implicated in numerous diseases. ET-1 is a potent mitogen regulator of smooth muscle tone, and inflammatory mediator that may play a key role in diseases of the airways, pulmonary circulation, and inflammatory lung diseases, both acute and chronic. This review will focus on the biology of ET-1 and its role in lung disease.